NUK - logo
E-viri
Recenzirano Odprti dostop
  • First Identified Case of Fa...
    Ameratunga, Rohan; Woon, See-Tarn; Sheppard, Mary N.; Garland, Jack; Ondruschka, Benjamin; Wong, Christopher X.; Stewart, Ralph A. H.; Tatley, Michael; Stables, Simon R.; Tse, Rexson D.

    Journal of clinical immunology, 04/2022, Letnik: 42, Številka: 3
    Journal Article

    Rationale Transient myopericarditis has been recognised as an uncommon and usually mild adverse event predominantly linked to mRNA-based COVID-19 vaccines. These have mostly occurred in young males after the second dose of mRNA COVID-19 vaccines. Objectives Fulminant necrotising eosinophilic myocarditis triggered by a variety of drugs or vaccines is an extremely rare hypersensitivity reaction carrying a substantial mortality risk. Early recognition of this medical emergency may facilitate urgent hospital admission for investigation and treatment. Timely intervention can lead to complete cardiac recovery, but the non-specific clinical features and rarity make early diagnosis challenging. Findings The clinical and pathological observations from a case of fatal fulminant necrotising myocarditis in a 57-year-old woman, following the first dose of the Pfizer-BioNTech vaccine, are described. Other causes have been discounted with reasonable certainty. Conclusion These extremely rare vaccine-related adverse events are much less common than the risk of myocarditis and other lethal complications from COVID-19 infection. The benefits of vaccination far exceed the risks of COVID-19 infection.